RECRUITING

A Multicenter Multinational Observational Study of Children With Hypochondroplasia

Talk to us

Conditions

Hypochondroplasia

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study will assess growth over time and the clinical course of HCH in children by collecting growth measurements and other variables of interest.

Official Title

A Multicenter Multinational Observational Study of Children With Hypochondroplasia

Quick Facts

Study Start:2023-11-27
Study Completion:2043-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06212947

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified to 15 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD
Inclusion CriteriaExclusion Criteria
  1. * Participants must be ≤ 15 years old at the time of signing the informed consent
  2. * Participants must have genetic confirmation of Hypochondroplasia diagnosis
  1. * Have a diagnosis of another genetic short stature condition other than Hypochondroplasia or a genetic variant known to cause another genetic syndrome associated with short stature
  2. * Received an investigational product or medical device within 6 months before the Screening visit

Contacts and Locations

Study Contact

Trial Specialist
CONTACT
1-800-938-4587
medinfo@bmrn.com

Principal Investigator

Medical Director, MD
STUDY_DIRECTOR
BioMarin Pharmaceutical

Study Locations (Sites)

Phoenix Children's Hospital
Phoenix, Arizona, 85016
United States
Cedars-Sinai Medical Center
Los Angeles, California, 90048
United States
UCSF Benioff Children's Hospital
Oakland, California, 94609
United States
Nemours Alfred I. Dupont Hospital for Children
Wilmington, Delaware, 19803
United States
Children's National Health System
Washington, District of Columbia, 20010
United States
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, 60611
United States
The Johns Hopkins University School of Medicine
Baltimore, Maryland, 21218
United States
Boston Children's Hospital
Boston, Massachusetts, 02115
United States
University of Minnesota Masonic Children's Hospital
Minneapolis, Minnesota, 55454
United States
University of Missouri
Columbia, Missouri, 65212
United States
Washington University School of Medicine in St. Louis
Saint Louis, Missouri, 63110
United States
Mount Sinai Kravis Children's Hospital
New York, New York, 10029
United States
Akron Children's Hospital
Akron, Ohio, 44307
United States
Nationwide Children's Hospital
Columbus, Ohio, 43205
United States
Cook Children's Endocrinology
Fort Worth, Texas, 76104
United States
Medical College of Wisconsin, Children's Hospital
Milwaukee, Wisconsin, 53226
United States

Collaborators and Investigators

Sponsor: BioMarin Pharmaceutical

  • Medical Director, MD, STUDY_DIRECTOR, BioMarin Pharmaceutical

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-11-27
Study Completion Date2043-12-31

Study Record Updates

Study Start Date2023-11-27
Study Completion Date2043-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Hypochondroplasia